Oxford Biomedica Signs a Five-Year Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC) for AZD1222

 Oxford Biomedica Signs a Five-Year Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC) for AZD1222

Oxford Biomedica Signs a Five-Year Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC) for AZD1222

Shots: 

  • Oxford Biomedica and VMIC entered into a five-year agreement for the manufacturing of adenovirus vector-based COVID-19 vaccine, AZD1222 for scaling up the production of the vaccine from the summer of 2020 to meet the demand in UK and EU
  • VMIC will provide manufacturing equipment whereas Oxford Biomedica will provide training and technical assistance to VMIC staff to accelerate the GMP manufacturing capabilities for AZD1222 at VMIC’s Harwell Science and Innovation Campus’ manufacturing site, expected to open in mid-2021
  • On May 28, 2020, AstraZeneca got global manufacturing, development and distribution responsibilities for AZD1222 from Oxford Biomedica under a clinical and commercial supply agreement

Click here to read full press release/ article | Ref: Oxford Biomedica | Image: Twitter

Related News: Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post